HBI Deals+Insights / News
GLP-1s are no longer regarded as “breakthrough treatments"; they are now seen as routine treatments for the management of chronic conditions. The rising demand for GLP-1s has also created pressure on supply chains, prompting increased investment in manufacturing and distribution, and vertical integration by major pharmaceutical companies — something that was highlighted by many speakers at the Jefferies London Healthcare Conference this week.





